Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open-Label Dose Escalation Trial to Investigate Safety and Tolerability of SNDX-6352 Monotherapy and SNDX-6352 in Combination With Durvalumab in Patients With Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

Trial Profile

Phase 1, Open-Label Dose Escalation Trial to Investigate Safety and Tolerability of SNDX-6352 Monotherapy and SNDX-6352 in Combination With Durvalumab in Patients With Unresectable, Recurrent, Locally-Advanced, or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Durvalumab (Primary) ; UCB 6352 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 07 Jan 2019 According to a Syndax Pharmaceuticals media release, top-line results from the study and a recommended Phase 2 dose are expected in the second quarter of 2019.
    • 31 Aug 2018 Biomarkers information updated
    • 07 Aug 2018 According to a Syndax Pharmaceuticals media release, dosing of patients with solid tumors in this trial evaluating the safety of SNDX-6352 continues as planned.Testing of SNDX-6352 in combination with durvalumab was recently initiated, and dosing of patients with SNDX-6352 as a monotherapy is ongoing. The Company anticipates identifying the recommended Phase 2 dose and schedule for SNDX-6352 monotherapy and in combination with durvalumab in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top